Guangzhou Wondfo Biotech (300482.SZ): plans to extend the "Knowledge City production base construction project" to June 2027.

On December 9th, Gelonghui reported that Guangzhou Wondfo Biotech (300482.SZ) announced that it held the seventh meeting of the fifth board of directors and the sixth meeting of the fifth board of supervisors on December 9, 2024, and reviewed and approved the "Proposal for Delaying Some Fundraising Investment Projects," agreeing to extend the time for the "Knowledge City Production Base Construction Project" to reach the predetermined usable state until June 2027, provided that there are no changes in the project implementation entity, implementation methods, use of raised funds, and investment scale. The sponsor institution issued a verification opinion, and this fundraising investment project delay is within the approval authority of the board of directors, and does not need to be submitted.

Gelonghui FinanceDec 9 16:46

Guangzhou Wondfo Biotech (300482) 2024 Third Quarter Report Review: Steady Revenue Growth, Continuous Progress in Overseas Certification of Products

Subject: The company released the third quarter report of 24 years, 24Q1-3, with revenue of 2.181 billion yuan (+8.83%), net income attributable to the parent company of 0.436 billion yuan (+9.04%), and non-net profit of 0.388 billion yuan (+14%).

Huachuang SecuritiesNov 12 07:32

Guangzhou Wondfo Biotech (300482): rapid expansion of international business, strong resilience shown in domestic business.

Event: On October 25, the company released the third quarter report of 2024: The revenue for the first three quarters of 2024 was 2.181 billion yuan, an 8.83% year-on-year increase; net income attributable to the parent company was 0.436 billion yuan, a year-on-year increase

Pacific SecuritiesOct 30 00:00

Express News | Guangzhou Wondfo Biotech's pathological products have received the first IVDR CE certification.

BreakingsOct 25 15:19

Wanfu Biotech: Report for the third quarter of 2024

SZSIOct 25 00:00 · Announcements

guangzhou wondfo biotech (300482.SZ) released its performance for the first three quarters, with a net income of 0.436 billion yuan, an increase of 9.04%.

Guangzhou Wondfo Biotech (300482.SZ) released its third-quarter report for 2024, with the company's revenue for the first three quarters reaching 2...

Zhitong FinanceOct 24 17:12